Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas - PubMed (original) (raw)
Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas
Fabio M Iwamoto et al. J Neurooncol. 2008 Jul.
Abstract
Purpose: To assess the frequency of chromosomes 1p and 19q deletions in gliomas and to correlate 1p deletion with prognosis in patients with grade 2 and grade 3 gliomas independently of histologic subtype.
Methods: We retrospectively evaluated 208 patients with WHO grade 2 and 3 gliomas who had 1p/19q molecular studies performed between 2000 and 2004. DNA was extracted from tumor tissue and germline material and evaluated by PCR using microsatellite markers for each chromosome.
Results: There were 113 men and 95 women with a median age at diagnosis of 40. Thirty-eight patients had a low-grade astrocytoma (A2), 58 low-grade oligodendroglioma (O2), 31 low-grade oligoastrocytoma (OA2), 21 anaplastic astrocytoma (A3), 37 anaplastic oligodendroglioma (O3), and 23 had an anaplastic oligoastrocytoma (OA3). Chromosome 1p analysis was performed in all patients and showed deletions in 105 patients (76% of O2, 42% of OA2, 21% of A2, 89% of O3, 17% of AO3, and 14% of A3). Chromosome 19q studies were performed in 118 patients and showed deletions in 46 (56% of O2, 45% of OA2, 27% of A2, 76% of O3, 11% of OA3 and 0% of A3). On multivariate analyses, chromosome 1p was a prognostic factor for prolonged PFS (HR = 1.75, P = 0.03) and OS (HR = 3.59, P = 0.02) in grade 2 gliomas but not for grade 3 (HR = 0.81, P = 0.7 for PFS; HR = 1.31, P = 0.7 for OS).
Conclusion: Chromosome 1p deletion is a significant positive prognostic marker in diffuse, grade 2 gliomas regardless of histologic subtype.
Similar articles
- Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas.
Sabha N, Knobbe CB, Maganti M, Al Omar S, Bernstein M, Cairns R, Çako B, von Deimling A, Capper D, Mak TW, Kiehl TR, Carvalho P, Garrett E, Perry A, Zadeh G, Guha A, Sidney Croul. Sabha N, et al. Neuro Oncol. 2014 Jul;16(7):914-23. doi: 10.1093/neuonc/not299. Neuro Oncol. 2014. PMID: 24470545 Free PMC article. - Treatment Outcomes in 1p19q Co-deleted/Partially Deleted Gliomas.
McNamara MG, Jiang H, Lim-Fat MJ, Sahebjam S, Kiehl TR, Karamchandani J, Coire C, Chung C, Millar BA, Laperriere N, Mason WP. McNamara MG, et al. Can J Neurol Sci. 2017 May;44(3):288-294. doi: 10.1017/cjn.2016.420. Can J Neurol Sci. 2017. PMID: 28488951 - Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma.
Aldape K, Burger PC, Perry A. Aldape K, et al. Arch Pathol Lab Med. 2007 Feb;131(2):242-51. doi: 10.5858/2007-131-242-CAOQLA. Arch Pathol Lab Med. 2007. PMID: 17284109 Review. - [Diagnostic and prognostic values of 1p and 19q deletions in adult gliomas: critical review of the literature and implications in daily clinical practice].
Fontaine D, Vandenbos F, Lebrun C, Paquis V, Frenay M. Fontaine D, et al. Rev Neurol (Paris). 2008 Jun-Jul;164(6-7):595-604. doi: 10.1016/j.neurol.2008.04.002. Epub 2008 May 21. Rev Neurol (Paris). 2008. PMID: 18565359 Review. French.
Cited by
- Depletion of the N6-Methyladenosine (m6A) reader protein IGF2BP3 induces ferroptosis in glioma by modulating the expression of GPX4.
Deng L, Di Y, Chen C, Xia J, Lei B, Li N, Zhang Q. Deng L, et al. Cell Death Dis. 2024 Mar 1;15(3):181. doi: 10.1038/s41419-024-06486-z. Cell Death Dis. 2024. PMID: 38429265 Free PMC article. - MD2 Is a Potential Biomarker Associated with Immune Cell Infiltration in Gliomas.
Zhao M, Li X, Chen Y, Wang S. Zhao M, et al. Front Oncol. 2022 Mar 17;12:854598. doi: 10.3389/fonc.2022.854598. eCollection 2022. Front Oncol. 2022. PMID: 35372062 Free PMC article. - Effects of 1p/19q Codeletion on Immune Phenotype in Low Grade Glioma.
Lv L, Zhang Y, Zhao Y, Wei Q, Zhao Y, Yi Q. Lv L, et al. Front Cell Neurosci. 2021 Jul 16;15:704344. doi: 10.3389/fncel.2021.704344. eCollection 2021. Front Cell Neurosci. 2021. PMID: 34335194 Free PMC article. - Molecular biomarkers and integrated pathological diagnosis in the reclassification of gliomas.
Ruiz MF, Gennaro MV, Bastone LC, Godoy AR, Torruella M, Perez GR. Ruiz MF, et al. Mol Clin Oncol. 2021 Aug;15(2):150. doi: 10.3892/mco.2021.2312. Epub 2021 May 31. Mol Clin Oncol. 2021. PMID: 34141429 Free PMC article. - Frequency of false-positive FISH 1p/19q codeletion in adult diffuse astrocytic gliomas.
Ball MK, Kollmeyer TM, Praska CE, McKenna ML, Giannini C, Raghunathan A, Jentoft ME, Lachance DH, Kipp BR, Jenkins RB, Ida CM. Ball MK, et al. Neurooncol Adv. 2020 Aug 27;2(1):vdaa109. doi: 10.1093/noajnl/vdaa109. eCollection 2020 Jan-Dec. Neurooncol Adv. 2020. PMID: 33205043 Free PMC article.
References
- Genes Chromosomes Cancer. 1992 Nov;5(4):348-56 - PubMed
- J Clin Oncol. 2006 Jun 20;24(18):2707-14 - PubMed
- Am J Surg Pathol. 2006 Jul;30(7):828-37 - PubMed
- Oncogene. 1999 Jul 15;18(28):4144-52 - PubMed
- J Clin Oncol. 2000 Feb;18(3):636-45 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials